Apr 11, 2018
Lytix Biopharma to present data on “turning COLD Tumors HOT” at AACR 2018

Lytix Biopharma will present data at the 2018 American Association for Cancer Research (AACR) Annual Meeting taking place from 14th – 18th April 2018 at McCormick Place North/South, Chicago, Illinois, US.

Dr Mikael J. Pittet, Associate Professor at Harvard Medical School, Senior Faculty of the Center for Systems Biology (CSB) at Massachusetts General Hospital (MGH) and Director of the CSB Cancer Immunology Program will present the data in a poster presentation from 8-12 am on Wednesday April 18. Previous experimental studies identified LTX-315’s ability to control cancer in mice grafted with various tumor cell lines triggering tumor-specific T cells. The  analyses has now been extended to conditional genetic mouse models of both melanoma (driven by Braf and Pten alterations) and soft tissue sarcoma (driven by Kras and P53 alterations). In these genetic models, cancer cells are derived from somatic cells that are transformed in their normal tissue microenvironment and progress to high-grade tumors that are poorly infiltrated by T cells and typically resist prescribed chemo- and immunotherapeutic treatments.


“We are excited to present this data at AACR in conjunction with Dr Pittet’s team which shows that LTX-315 not only delays tumor progression substantially in both models, but also profoundly alters the tumor microenvironment, most notably characterized with CD8+ T cell, NK cell and dendritic cell infiltration. A similar transition from a ‘cold’ to a ‘hot’ tumor microenvironment is seen in patients with melanoma, sarcoma and breast cancer after treatment with LTX-315. Furthermore, CD8+ T cell depletion in mice abrogated long-term antitumor efficacy of LTX-315, indicating that these cells are required for drug-induced tumor control. Importantly, the ability to convert non-T-cell-infiltrated tumors into ones that display antitumor T cell immunity opens the possibility to prime and make unresponsive tumors sensitive for systemic immune treatments,” commented Dr Edwin Klumper, CEO of Lytix Biopharma.


April 18, 2018, 8:00 AM - 12:00 PM
Section 25 Session PO.CL06.08 - Immunomodulatory Agents and Interventions 3

5549 / 5 - Antitumor efficacy of the oncolytic peptide LTX-315 in genetic mouse models that resist conventional chemo- and immunotherapeutic treatments

M. J. Pittet1, H-W. Liao1, B. Sveinbjørnsson2, Ø. Rekdal2; 1Massachusetts Gen. Hosp., Boston, MA, 2Lytix Biopharma, Tromso, Norway